|Articles|December 8, 2022
- Pharmaceutical Executive-12-01-2022
- Volume 42
- Issue 12
Pharmaceutical Executive, December 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive December 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 3 years ago
2023 Pipeline Report: Testing the Limitsalmost 3 years ago
Business and Passionalmost 3 years ago
Back in Person, Sparks Could Fly at Upcoming J.P. Morgan Conferencealmost 3 years ago
Aligning Trust and Transparency in Brand Messagingalmost 3 years ago
Pharma Needs to Look Internally for New Leadershipalmost 3 years ago
Seeking Concrete Solutions to Europe’s Supply Problemsalmost 3 years ago
Pandemic and Politics Shaped Pharma and FDA in 2022almost 3 years ago
Medical Affairs Uptickalmost 3 years ago
Virtual Medical Affairs Audits: A Viable AlternativeNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
